Drug Profile


Latest Information Update: 23 Mar 2009

Price : $50

At a glance

  • Originator Eli Lilly; Novo Nordisk
  • Class Amino acids; Antihyperglycaemics; Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 23 Mar 2009 Discontinued for Diabetes mellitus in Denmark (SC)
  • 23 Mar 2009 Discontinued for Diabetes mellitus in USA (SC)
  • 26 Feb 2001 No-Development-Reported for Diabetes mellitus in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top